Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12797263 | 0.85 | MAPT (0.36) | ALDH1A1POLBCYP3A4CYP19A1CYP11B1 | |
| SCHEMBL12848919 | 0.79 | CYP17A1 (0.35) | PTGS2CYP3A4CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL10272852 | 0.78 | PDGFRB (0.43) | ALDH1A1POLBCYP17A1CYP19A1CYP11B1 | |
| SCHEMBL2552755 | 0.77 | ALDH1A1 (0.55) | TDP1ALDH1A1TSHRPOLBCYP3A4 | |
| SCHEMBL527993 | 0.77 | PDE4B (0.48) | TDP1ALDH1A1TSHRNPBWR1POLB | |
| SCHEMBL7079453 | 0.74 | HSD17B10 (0.47) | TDP1ALDH1A1TSHRNPBWR1CYP3A4 | |
| SCHEMBL527341 | 0.73 | CYP46A1 (0.46) | TDP1ALDH1A1POLBCYP3A4CYP17A1 | |
| SCHEMBL526783 | 0.71 | CYP19A1 (0.49) | TDP1TSHRCYP17A1CYP19A1CYP11B1 | |
| SCHEMBL16472053 | 0.71 | MEN1 (0.53) | TDP1ALDH1A1TSHRPTGS2POLB | |
| SCHEMBL9683795 | 0.70 | TDP1 (0.50) | TDP1ALDH1A1TSHRPOLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2009089305-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | TDP1 4423/4885ALDH1A1 644/4885TSHR 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.